ACTBP12: A Drug Target / Disease Biomarker (G100462767)

Target Name: ACTBP12

NCBI ID: G100462767

ACTBP12

Other Name(s): ACTGP5 | ACTB pseudogene 12 | Actin, beta pseudogene 12

ACTBP12: A Drug Target / Disease Biomarker

ACTBP12 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the actinin family, which is known for their role in cell signaling and cytoskeletal organization.

One of the most interesting aspects of ACTBP12 is its potential as a drug target. The actinin family has been shown to play a role in a variety of physiological processes, including cell signaling, cytoskeletal organization, and inflammation. As a result, ACTBP12 has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the potential of ACTBP12 as a drug target is its involvement in a variety of cellular signaling pathways. Actinins have been shown to play a role in the regulation of cell signaling pathways, including the regulation of cell proliferation, differentiation, and survival. In addition, ACTBP12 has been shown to interact with a variety of signaling molecules, including tyrosine kinases, mitochondrial proteins, and intracellular signaling molecules.

This interaction between ACTBP12 and these signaling molecules makes it a potential target for a variety of drugs. For example, inhibitors of tyrosine kinases, which are known to interact with ACTBP12, have been shown to be effective in treating a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Similarly, drugs that inhibit the activity of mitochondrial proteins, which are also known to interact with ACTBP12, have been shown to be effective in treating a variety of neurodegenerative diseases and cancer.

In addition to its potential as a drug target, ACTBP12 also has a number of potential applications as a biomarker. The actinin family is known for its ability to form a stable cytoskeleton, which is important for the proper functioning of cells. As a result, ACTBP12 has been shown to be a useful biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key advantages of ACTBP12 as a biomarker is its stability and its ability to be easily detected and measured. This makes it a useful tool for the diagnosis and monitoring of a variety of diseases. For example, ACTBP12 has been used as a biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, ACTBP12 has also been used as a biomarker for a variety of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

In conclusion, ACTBP12 is a protein that has the potential to be a drug target for a variety of diseases. Its involvement in cellular signaling pathways and its ability to form a stable cytoskeleton make it a promising target for a variety of neurodegenerative diseases and autoimmune disorders. Further research is needed to fully understand the role of ACTBP12 as a drug target and its potential as a biomarker.

Protein Name: ACTB Pseudogene 12

The "ACTBP12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTBP12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets